The approval covers the use of Enhertu in both the neoadjuvant and adjuvant treatment settings for adult patients.
In the neoadjuvant setting, the therapy is approved for adults with HER2-positive stage 2 or stage 3 breast cancer. Credit: Arif biswas / Shutterstock.com.
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for two new indications in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
Data from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials support these approvals. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
